Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 4/20 | 0.57 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.56 |
| ▸ | MEN1 | O00255 | 4/20 | 0.56 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.54 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.54 |
| ▸ | RECQL | P46063 | 1/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.51 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.50 |
| ▸ | HTT | P42858 | 1/20 | 0.50 |
| ▸ | GAA | P10253 | 1/20 | 0.49 |
| ▸ | POLB | P06746 | 1/20 | 0.48 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.46 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.46 |
| ▸ | TSHR | P16473 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3134886 | 0.94 | MEN1 (0.65) | LMNAKMT2AMEN1SMN1; SMN2KDM4E | |
| SCHEMBL12970708 | 0.92 | ALDH1A1 (0.65) | LMNAKMT2AMEN1SMN1; SMN2KDM4E | |
| SCHEMBL12970709 | 0.92 | ALDH1A1 (0.65) | LMNAKMT2AMEN1SMN1; SMN2KDM4E | |
| SCHEMBL3721741 | 0.80 | LMNA (0.63) | LMNAKMT2AMEN1SMN1; SMN2KDM4E | |
| SCHEMBL11673735 | 0.79 | GSK3B (0.42) | LMNA | |
| SCHEMBL5466144 | 0.79 | LMNA (0.61) | LMNAKMT2AMEN1SMN1; SMN2KDM4E | |
| SCHEMBL12572048 | 0.78 | KMT2A (0.72) | LMNAKMT2AMEN1SMN1; SMN2KDM4E | |
| SCHEMBL5649036 | 0.77 | GSK3B (0.53) | LMNASMN1; SMN2ALDH1A1MAPK1HTT | |
| SCHEMBL14844102 | 0.77 | SMN1; SMN2 (0.61) | LMNAKMT2AMEN1SMN1; SMN2KDM4E | |
| SCHEMBL3387592 | 0.76 | ALDH1A1 (0.70) | LMNAKMT2AMEN1SMN1; SMN2KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100004441-A1 | N-(5-Membered Aromatic Ring)-Amido Anti-Viral Compounds | SCHMITZ FRANZ ULRICH | 2010-01-07 | — | — | US | disclosed |
| US-7595398-B2 | N-(5-membered aromatic ring)-amido anti-viral compounds | SMITHKLINE BEECHAM CORPORATION (US) | 2009-09-29 | — | — | US | disclosed |
| EP-1971597-A2 | N-(5-MEMBERED HETEROAROMATIC RING)-AMIDO ANTI-VIRAL COMPOUNDS | GENELABS TECHNOLOGIES, INC. (US) | 2008-09-24 | — | — | EP | disclosed |
| US-20070265265-A1 | N-(5-MEMBERED AROMATIC RING)-AMIDO ANTI-VIRAL COMPOUNDS | GENELABS TECHNOLOGIES, INC. | 2007-11-15 | — | — | US | disclosed |
| WO-2007070600-A2 | N-(5-MEMBERED HETEROAROMATIC RING)-AMIDO ANTI-VIRAL COMPOUNDS | GENELABS TECHNOLOGIES, INC. (US) | 2007-06-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100004441-A1 | N-(5-Membered Aromatic Ring)-Amido Anti-Viral Compounds | ZC3HAV1, ZC3HAV1L, HAVCR2 | LMNA 1094/4885KMT2A 2419/4885MEN1 3838/4885 |
| US-20070265265-A1 | N-(5-MEMBERED AROMATIC RING)-AMIDO ANTI-VIRAL COMPOUNDS | ZC3HAV1, ZC3HAV1L, HAVCR2 | LMNA 1094/4885KMT2A 2419/4885MEN1 3838/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.